Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Integra LifeSciences Holdings Corporation (IART) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / October 7, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Integra LifeSciences Holdings Corporation ("Integra LifeSciences" or "the Company") (NASDAQ:IART). Investors who purchased Integra LifeSciences securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/integra-lifesciences-holdings-corporation-iart-class_action_lawsuit.

Integra LifeSciences Investigation Details

On October 2, 2026, Integra LifeSciences Holdings Corporation lowered its full-year 2026 guidance and reported preliminary third-quarter revenue below analyst estimates. The Company attributed the guidance reduction and revenue shortfall to a July flood at its Cincinnati manufacturing facility, which damaged production assets and disrupted product supply. Integra stated that the disruption is expected to reduce fourth-quarter revenue by approximately $15 million to $20 million, with full manufacturing operations at the facility not expected to resume until the second quarter of 2027. During the Company's July 29, 2026, earnings call, Chief Financial Officer Lea Daniels Knight had stated that Integra did "not expect the event to have a material impact on our revenue or EPS guidance for 2026." Following this news, Integra's stock price fell nearly 20% in midday trading on October 2, 2026.

What's Next for Integra LifeSciences Investors?

If you are aware of any facts relating to this investigation or purchased Integra LifeSciences securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/integra-lifesciences-holdings-corporation-iart-class_action_lawsuit. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Integra LifeSciences Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Integra LifeSciences Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller

Bronstein, Gewirtz & Grossman, LLC

917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC